Cowen resumed coverage of Exagen with a rating of Outperform and set a new price target of $26.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/5/2022 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 11/11/2021 | $33.00 → $30.00 | Overweight | Keybanc |
| 10/15/2021 | $26.00 | Outperform | Cowen |
10-Q - EXAGEN INC. (0001274737) (Filer)
10-Q - EXAGEN INC. (0001274737) (Filer)
8-K - EXAGEN INC. (0001274737) (Filer)
CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (NASDAQ:FLGT), a full-service genomic testing company built around a foundational technology platform. He has held that position since February 2016 and led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021, during the COVID-19 era. Mr. Kim has over 30 years working in accounting and finance, and over 15 years as a Chief Financial Officer of several public
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. Since 2012, AVISE CTD has delivered diagnostic clarity where overlapping clinical symptoms and ambiguous disease states make it difficult to arrive at a differen
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Company presentation by John Aballi, President and CEO on Thursday, November 21, 2024, at 3:00 p.m. EST at the Westin NY Grand Central Hotel. Management will also participate in one-on-one investor meetings. Evercore HEALTHCONx Conference Company presentation by John Aballi, President and CEO on Wednesday, December 4, 2024, at 12:30 p.m. EST at The Lowes Coral Gables Hotel in Coral Gables
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2024 and recent corporate updates. Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands, except ASP data) Revenue $12,507 $13,416 $41,986 $38,783 Gross margin 55.8% 57.4% 58.7% 54.9%Operating expenses (including COGS) $17,170 $18,485 $52,239
Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $5 to $7.
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.22 percent. This is a 56.82 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $14.415 million which beat the analyst consensus estimate of $13.095 million by 10.08 percent. This is a 28.36 percent increase over sales of $11.230 million the same period last year.
4 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
3 - EXAGEN INC. (0001274737) (Issuer)
SC 13G/A - EXAGEN INC. (0001274737) (Subject)
SC 13G/A - EXAGEN INC. (0001274737) (Subject)
SC 13G/A - EXAGEN INC. (0001274737) (Subject)
4 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2024 and recent corporate updates. Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands, except ASP data) Revenue $12,507 $13,416 $41,986 $38,783 Gross margin 55.8% 57.4% 58.7% 54.9%Operating expenses (including COGS) $17,170 $18,485 $52,239
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024, before the market opens on Tuesday, November 12, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT). Interested parties may access the conference call by dialing (201) 389-0918 (U.S.) or (877) 407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.c
CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024. Highlights: Recognized record total revenue of $15.1 million in the second quarter of 2024.Delivered gross margin of 60.1% in the second quarter of 2024, compared to a gross margin of 58.7% in the second quarter of 2023. AVISE® CTD trailing twelve-month average selling price (ASP) of $401, a 25.3% increase over the trailing twelve-month ASP in the second quarter of 2023. Net loss of $3.0 million in the second quarter of 2024, a 40.8% improvement over the second quarter of 2023. Adjusted E
KeyBanc Capital Markets downgraded Exagen from Overweight to Sector Weight
Keybanc reiterated coverage of Exagen with a rating of Overweight and set a new price target of $30.00 from $33.00 previously
Cowen resumed coverage of Exagen with a rating of Outperform and set a new price target of $26.00